(Press-News.org) Bowel cancer is often driven by mutations in one of several different genes, and a patient can have a cancer with a different genetic make-up to another patient's cancer. Identifying the molecular alterations involved in each patient's cancer enables doctors to choose drugs that best target specific alterations.
However, it is also becoming clear that while some cancers may be driven by a single gene mutation, individual tumours are often composed of groups of cancer cells, with each group having different molecular alterations from the others. This is known as intra-tumour heterogeneity and it could have important consequences on the efficacy of therapies: in these "mixed" tumours, some tumour cell clusters might be sensitive to a targeted therapy while others are resistant.
Now, for the first time, a study published in the leading cancer journal Annals of Oncology [1] today (Monday), has quantified the different mutational profiles of these clusters of cells in individual tumours in patients with bowel cancer that has spread to other parts of the body (metastasised). The researchers in Italy have correlated the intra-tumour heterogeneity with the way the patients responded to specific drugs, such as cetuximab, an epidermal growth factor receptor (EGFR) inhibitor, which is a common treatment for patients with metastatic bowel cancer.
"Our study has shown there is a high degree of variability between different groups of cancer cells within one tumour, and we have been able to quantify this for the first time. The variability is likely to affect patients' responses to drugs targeting specific genetic mutations, and our results also suggest that there is a subset of bowel cancer patients in whom resistance to anti-EGFR drugs may be driven by the complex mutational make-up of the tumour, rather than the molecular alteration of a single gene," said Dr Nicola Normanno, Director of the Cell Biology and Biotherapy Unit and Director of the Laboratory of Pharmacogenomics, Centro di Ricerche Oncologiche di Mercogliano, at the Istituto Nazionale Tumori "Fondazione Giovanni Pascale" IRCCS, Naples, Italy, who led the study.
"It is difficult to predict when these findings can be translated into the clinic and we don't want to create false expectations in the patients. However, we feel that by being able to quantify the relevant mutations, we will be able to improve personalised medicine for patients with bowel cancer and possibly with other types of cancers," he said.
The researchers used "next generation sequencing", which can provide information on several different genes in a single analysis, to investigate the mutational profiles of 182 tumour samples taken from patients in the CAPRI-GOIM trial - a multi-centre study of patients with metastatic colorectal cancer who were treated with chemotherapy and cetuximab, followed by a slightly different chemotherapy with or without cetuximab every two weeks when their cancer progressed [2,3].
To quantify the different mutational profiles in each tumour, the researchers developed a "Heterogeneity Score" (HS), which corresponded with the proportion of cancer cells carrying a specific mutation. An HS of 100 suggests that all the cancer cells carry a specific mutation; an HS of less than 100 means that only a fraction of the cells are mutant; while an HS of more than 100 implies a structural variation in DNA involving either a gain of a mutant form of a gene or the loss of the "normal" (wild-type) form of the gene - a process known as copy number variation (CNV).
Dr Normanno said: "By using this scoring system, we found that different genes involved in bowel cancer behave in a different manner; for example, when a tumour has a mutation in the KRAS or NRAS genes, usually all the cells are mutant, whereas for other genes such as BRAF and PIK3CA only a fraction of tumour cells is mutant. In addition, we identified tumours that are clearly formed by multiple groups of cells with different molecular alterations."
The average HS for mutations in the KRAS and NRAS genes was 87 and 103 respectively, suggesting that the majority of the cancer cells carried the mutations. In contrast, the average HS for mutations in the BRAF and PIK3CA genes was 54 and 60, suggesting that only a fraction of cancer cells carried the mutant forms of the genes.
The researchers also found that 70% of patients with a KRAS HS of less than 33 responded to cetuximab, while only 46% of patients with a KRAS HS greater than 33 responded. However, the length of time that both groups survived without their disease progressing was similar: 8 and 8.4 months respectively. Patients in the "low KRAS" group had a higher frequency of additional mutations in the PIK3CA gene compared to those in the "high KRAS" group.
"This suggests that even if a patient has a lower HS score for KRAS and so responds well initially to EGFR-inhibitor treatments such as cetuximab, either other cancer cells take over to resist the treatment and drive the cancer, or another mutation such as PIK3CA continues to drive the cancer," said Dr Normanno. "This may mean that a treatment approach that uses a combination of drugs targeting different mutations may be more effective for these patients."
The principal investigator of the CAPRI-GOIM trial is Professor Fortunato Ciardiello of the Second University of Naples. Now, the researchers are planning to use next generation sequencing and their scoring system in large, prospective clinical trials of bowel cancer patients being treated with EGFR-targeting drugs, and in sub-groups of patients carrying specific mutations such as BRAF, in order to assess further the correlation between HS and patients' response and outcome.
INFORMATION:
[1] "Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial", by N.Normanno et al, on behalf of the CAPRI-GOIM investigators. Annals of Oncology. doi:10.1093/annonc/mdv176
[2] "CAPRI-GOIM" stands for "Cetuximab after progression in KRAS wild type colorectal cancer patients" (CAPRI) and "Gruppo Oncologico dell'Italia Meridionale" (GOIM).
[3] The first-line chemotherapy was FOLFIRI (infusional 5-FU/folinic acid/irinotecan), followed by a second-line FOLFOX chemotherapy (infusional 5-FU/folinic acid/oxaliplatin).
Streptococcus pneumoniae is a major human pathogen and is known to be associated with increased risk of fatal heart complications including heart failure and heart attacks.
As Streptococcus pneumoniae is a respiratory pathogen that does not infect the heart, however, this association with heart problems has puzzled clinicians and researchers, particularly as even prompt use of antibiotics does not provide any protection from cardiac complications.
A multidisciplinary research team, led by Professor Aras Kadioglu and Professor Cheng-Hock Toh at the University of Liverpool, ...
WASHINGTON, D.C., May 18, 2015 -- Human beings have unique voices -- from the deep, resonating bass of James Earl Jones to the raspy melodies sung by Broadway star Carol Channing -- and we routinely recognize individuals based solely on the way they sound, for example over the telephone, on a music CD or in an animated film.
The same theory that explains individual differences in human speech has recently been applied to other members of the animal kingdom, including dogs and deer. Now researchers from Syracuse University in New York are working to understand whether ...
Predatory seals are constraining the recovery of cod stocks in Scottish West coast waters, research led at the University of Strathclyde suggests.
Losses of cod, through fishing and natural causes, have remained high for many years and have caused long-term decline in the stock - in some years, fishing removed around 50% of the total weight of the stock. The study found that, although fishing has now halved, predation by seals has rapidly increased to compensate, eating up more than 40% of the total stock.
Seals have, historically, been anecdotally blamed for the reduction ...
Stanford computer scientists have shown how crowdfunding websites can use data science to boost cash value of donations. Their research confirms, among other findings, the importance of a timely thank you.
It's common courtesy to say thanks when receiving a gift, and common sense to think that givers might be generous again if they felt good about their prior gift.
Now Stanford computer scientists have shown how crowdfunding websites like Kickstarter and DonorsChoose.org can use data science to apply these folk wisdoms systematically, and on a large scale, to greatly ...
PISCATAWAY, NJ - Among people who use medical cannabis for chronic pain, those who also take prescription pain medications are not at increased risk for serious alcohol and other drug involvement, according to a study in the May issue of the Journal of Studies on Alcohol and Drugs.
Although medical cannabis is being used increasingly often as an alternative to opioids for chronic pain, in many patients it is being used in conjunction with opioids. This use has raised concerns that the combination could increase the risk of patients using substances such as alcohol and ...
New York, NY, May 18 2015 -- Shiftwork is an occupational health risk of growing significance because it is becoming more common and because of its potential influence on health outcomes, possibly increasing health differences between workers of higher vs lower socioeconomic status. A new study from the University of Wisconsin School of Medicine and Public Health determined that employees who work shifts outside of a 9-to-5 schedule are more likely to be overweight and experience sleep problems, and possibly more likely to develop metabolic disorders, such as diabetes, ...
(Boston) -- A new test co-developed by a Boston University School of Medicine (BUSM) researcher will allow patients suspected of having lung cancer to be subjected to fewer and less-invasive tests to determine if they have the disease.
"We are seeing an increase in the number of lesions suspicious for lung cancer found on chest imaging of current and former smokers. In the past, these patients have been subjected to invasive tests when traditional bronchoscopy tests prove inconclusive. Today's announcement provides physicians and patients with an additional piece of scientifically ...
The Lancet Diabetes & Endocrinology journal is pleased to announce that the following Series of papers on depression and diabetes will be published on Monday 18 May to coincide with the 2015 Annual Meeting of the American Psychiatric Association (APA).
The Series is accompanied by another Series of papers on Diabetes and psychotic disorders, available in the latest issue of The Lancet Psychiatry.
Constructs of depression and distress in diabetes: time for an appraisal [Embargo: 6:30pm [New York time] Sunday 17 May, 2015]
The link between depression and diabetes: the ...
ATS 2015, DENVER -- Regular use of aspirin may help slow the progression of early emphysema, according to new research presented at the 2015 American Thoracic Society International Conference.
"Other than smoking cessation and avoidance, there are no known methods for reducing the risk of developing emphysema," said researcher Carrie Aaron MD, of the Columbia University Medical Center in New York. "In our large general population sample, we found that regular aspirin use (three or more days per week) was associated with a slower progression of percent emphysema on computed ...
A relatively new, easier to implement, and better-tolerated method to provide supplemental oxygen to patients at risk of respiratory failure after surgery did not result in a worse rate of treatment failure compared to a more commonly used method, according to a study appearing in JAMA. The study is being released to coincide with its presentation at the American Thoracic Society 2015 International Conference.
After cardiothoracic surgery, acute respiratory failure is common and associated with an increased risk of illness and death. When low-flow oxygen therapy is insufficient ...
